Conclusions: With the development of recombinant DNA techniques, it has become possible to develop new biologic therapies that can be designed to specifically alter physiological responses. These new ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

In patients with psoriasis, biologics may reduce ocular surface and corneal inflammation — especially dry eye, conjunctivitis ...

Patients with psoriasis who have active cancer or who have had cancer within 5 years can safely use biologics.

Please provide your email address to receive an email when new articles are posted on . This study compared risankizumab with other biologics in both biologic-naïve and biologic-experienced patients.

Please provide your email address to receive an email when new articles are posted on . The majority of patients and clinicians agreed with the use of as-needed biologic therapy for psoriasis.

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...

Inflammatory markers can indicate treatment efficacy and predict super-responder status in patients with psoriasis treated with biologics, according to one study. Blood count–derived inflammatory ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

Some 25% of patients with psoriasis eventually develop psoriatic arthritis, but the risk may be mitigated with targeted therapies. This single-center study found that progression to PsA was more ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a Canadian cohort study showed. For more ...

For patients with plaque psoriasis who initiated treatment with a first-line biologic, the average treatment cost more than doubled from 2007 to 2021 as more patients started newer IL-17 and IL-23 ...